MAGNETIC RESONANCE IMAGING in Superficial Soft Tissue Masses

October 13, 2021 updated by: Fatma Alzahraa Mohamed Hassan Anwar, Assiut University

Role of MAGNETIC RESONANCE IMAGING in Characterization of Superficial Soft Tissue Masses

This study responds to these raise up questions: Can we use Diffusion Weighted MR complemented with numerical ADC values & in association with routine MRI in the discrimination between different malignant and benign superficial soft tissue masses.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

In the clinical practice, there is a large number & variety of superficial soft tissue masses. The differentiation of such masses represents a major obstacle for the surgeons. Benign &malignant neoplasms as well as non-neoplastic swellings may have similar clinical presentation. The differentiation between malignant & benign superficial soft tissue neoplasms is required for appropriate therapeutic planning and decisions. Masses can be characterized in terms of their size, number, component &vascularity using US and Doppler US. However, US is operator dependent & may display a number of artifacts that can result in misinterpretation. So MRI is superior in the assessment of such soft tissue masses due its brilliant soft tissue discrimination. Some features that will help distinguish malignant from benign lesions are evident on MRI examination such as signal characteristics,enhancement pattern,margin,lobulation,necrosis, haemorrhage,internal septation,peritumoral edema and extension through the deep fascia .However very forcful tumors may show benign behavior & appear similar to benign masses , Thus further histopathology is required for accurate diagnosis. Diffusion weighted MRI visualizes the random microscopic motion of molecules. Diffusion-weighted imaging (DWI) is the technique which allows measurement of the Brownian motion of water in the tissue microenvironment depending on the organization of the tissue, integrity of cell membranes, and tortuosity of extracellular space. Apparent Diffusion Coefficient (ADC) is a numerical parameter which is calculated from DWI. Previously, DWI technique was used with great success in the central nervous system (CNS), in the differentiation between benign and malignant tumors in addition to its great value in early diagnosis of recent strokes. Nowadays, DWI was used in the differentiation between malignant and benign soft tissue masses. Malignant tumors have abundant cellularity than benign tumors hence they have more restricted diffusion. The addition of quantitative ADC values plays a fundamental role in more accurate diagnosis of malignant superficial soft tissue neoplasms.

Study Type

Observational

Enrollment (Anticipated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients with superficial soft tissue masses

Description

Inclusion Criteria:

  • patients with superficial soft tissue masses clinically
  • patients underwent us detection of superficial soft tissue masses
  • uncharactized superficial soft tissue mass by other modalities

Exclusion Criteria:

  • MRI claustrophobia
  • recurrent cases
  • patients under treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
benign and malignant masses
Time Frame: from october 2021 to october2022
The discrimination between benign and malignant superficial soft tissue mass by Non invasive available technique
from october 2021 to october2022

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Type of malignant superficial soft tissue masses
Time Frame: From October 2021 to October 2022
Differentiation type of malignant superficial soft tissue masses
From October 2021 to October 2022

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Local invasion of malignant superficial soft tissue masses
Time Frame: From October 2021 to October 2022
Detection local invasion of malignant superficial soft tissue masses
From October 2021 to October 2022

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

October 1, 2021

Primary Completion (ANTICIPATED)

October 1, 2022

Study Completion (ANTICIPATED)

March 1, 2023

Study Registration Dates

First Submitted

September 26, 2021

First Submitted That Met QC Criteria

October 13, 2021

First Posted (ACTUAL)

October 15, 2021

Study Record Updates

Last Update Posted (ACTUAL)

October 15, 2021

Last Update Submitted That Met QC Criteria

October 13, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • mri in soft tissue

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Soft Tissue Masses

Clinical Trials on MAGNETIC RESONANCE IMAGING

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe